Journal of Multidisciplinary Healthcare

Next-Generation Vaccines and Innovative Drug Delivery Systems: From Development to Public Health Impact

Vaccines are widely recognized as a pillar of public health, saving millions of lives annually by preventing infectious diseases and contributing to herd immunity. Recently, vaccines have experienced significant growth with the advancements in nanotechnology and vaccine technologies, including mRNA vaccines, viral vector platforms, and recombinant protein vaccines. Especially with the approval of mRNA LNP vaccine for COVID 19, research in vaccines has shifted to the development of mRNA-based vaccines with the aid of lipid nanoparticle delivery systems. Innovations in delivery technologies, including microneedle patches, intranasal delivery, and lipid nanoparticles, have revolutionized the way vaccines are administrated and stored. These advances shift the trend of conventional vaccines toward designing more efficient, precise, and patient-friendly immunization systems.

These developments are critically important in overcoming the challenges of designing the vaccine delivery systems, administration, and addressing concerns related to vaccine hesitancy faced by public health. Global experiences with pandemics, emerging infectious diseases, and persistent inequity in vaccine access have underscored the need for scalable, acceptable, and reliable vaccination strategies.  However, there are increasing reports on vaccines acceptance, hesitancy, perspectives from the public, and observations from vaccinated populations, and these are highly important apart from focusing solely on advancements in vaccines development. Hence, understanding practical concerns about vaccines from a public health point of view and integrating emerging innovations with practical implementation is of utmost importance.

This Article Collection provides a multidisciplinary platform for research spanning vaccine development, delivery technologies, and their broader public health implications. It bridges the gaps between innovations in vaccine development and delivery technologies and their implication in public health, ultimately supporting more effective and accessible vaccination programs worldwide.

We welcome original research articles, reviews, and short communications regarding (but not limited to):

• Development and optimization of next-generation vaccines, e.g., mRNA vaccines, DNA vaccines, siRNA vaccines, viral vectors, and protein subunit vaccines
• Design and evaluation of innovative vaccine delivery systems and adjuvant technologies
• Stability, storage, and cold chain considerations for advanced vaccine formulations
• Alternative routes of administration, including mucosal and transdermal delivery
• Safety profiles, immunogenicity, and effectiveness of vaccines
• Public perception, vaccine hesitancy, and acceptance of vaccines
• Implementation challenges and strategies in low- and middle-income countries
• Policy, equity, and global access to vaccines

Submission Instructions:

During submission (in step 2 "About paper"), you will see a question asking "Are you interested in submitting to an article collection?" Please select the radio dial for "Yes". Then select "Next-Generation Vaccines and Innovative Drug Delivery Systems: From Development to Public Health Impact" from the drop down menu.

Authors submitting to this Collection are welcome to enter the promo code 30046 for a 10% discount off our Article Publishing Charge. The promo code field appears in step 3 "Billing address".

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author submission instructions prior to submission.

Please contact Krista Thom ([email protected]) with questions about this Article Collection.

Guest Advisors:

Dr. Geetha Vaskuri is a researcher at the University of Kansas, USA, specializing in vaccine formulation development and delivery. Her work is primarily focused on formulation development, analytical characterization, drug delivery, nanomedicine, and pharmacokinetics. She worked as a researcher in UTHSC, Memphis, USA and completed her Ph.D. in the field of pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hyderabad, India following a master’s degree from the same institute. Her contributions to research have been recognized through the publication of more than 35 research and review papers in peer-reviewed journals. Her work aims to develop effective formulation and delivery strategies.

Dr. Nagavendra Kommineni is currently working as Scientist II in Formulation and Process Development at Thermo Fisher Scientific Inc, Cincinnati, USA. He previously worked as a Research Associate at Population Council at Rockefeller University, New York, USA and Florida A&M University, Tallahassee, USA. He completed his master’s degree and Ph.D. in pharmaceutics from NIPER Hyderabad, India. His areas of expertise include solid oral dosage forms, liposomal technology for delivering small molecules, stem-cell-derived exosome delivery of small molecules, lipid nanoparticles, topical and transdermal product development, development of complex and sterile injectables, and the development of nanotechnology-based products for HIV and contraception. He has published over 60 research and review articles as well as book chapters. In recognition of his research accomplishments, he has been listed among the world’s top 2% of scientists, as published by Stanford University in Elsevier, for 3 consecutive years (2023-2025).

Disclosure: Neither Dr. Vaskuri nor Dr. Kommineni declare any conflicts of interest.